Helicobacter Pylori
US-FDASourced from openFDA
GET
/api/v1/drug/helicobacter-pyloriIndications
Sourced from openFDA- HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to H. Pylori infection including upper abdominal pain or discomfort, loss of appetite, belching, nausea, vomiting and fatigue.** **These statements are based upon homeopathic principles.ICD-10: R11.2
Dosage & administration
Sourced from openFDADIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
Warnings & precautions
Sourced from openFDAKeep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. If pregnant or breast-feeding, ask a health professional before use. Tamper seal: "Sealed for Your Protection." Do not use if seal is broken or missing.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
63 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Depression2946%
- 2Dyspnoea2844%
- 3Sleep Disorder2844%
- 4Sleep Disorder Due To A General Medical Condition2844%
- 5Therapeutic Product Effect Incomplete2844%
- 6Anxiety2743%
- 7Asthma2743%
- 8Breast Cancer2743%
- 9Chest Discomfort2743%
- 10Chronic Obstructive Pulmonary Disease2743%
- 11Cough2743%
- 12Eosinophilia2743%
- 13Hypertension2743%
- 14Malaise2743%
- 15Mental Disorder2743%
Literature
Recent PubMed references pinned to Helicobacter Pylori as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Tailored screening and eradication of Helicobacter pylori at a subnational level of China: multicenter observational studies in Ya'an city and a rapid meta-analysis in Sichuan province.Frontiers in public health · 2026 · Wang L, Chen O, Chen XZ, et al.PMID 42245335DOI 10.3389/fpubh.2026.1774904
- Integrated virulence-resistance profiling of Helicobacter pylori reveals context-dependent pathogenic signatures in gastric cancer.Frontiers in cellular and infection microbiology · 2026 · Mbuthia O, Mehmood A, Mahjabeen I, et al.PMID 42239538DOI 10.3389/fcimb.2026.1812371
- Epstein-Barr Virus and Helicobacter pylori Co-Infection in Gastric Cancer: A Systematic Review and Meta-Analysis of Case-Control and Cross-Sectional Studies.Asian Pacific journal of cancer prevention : APJCP · 2026 · Mohseni G, Heydari K, Hoseini A, et al.PMID 42226568DOI 10.31557/APJCP.2026.27.5.1937
- Nickel binding shifts Helicobacter pylori HypA toward compact conformations.Journal of inorganic biochemistry · 2026 · Ciurli S, Mazzei L, Zambelli B, et al.PMID 42217269DOI 10.1016/j.jinorgbio.2026.113350
- Burden of Helicobacter pylori infection in children and adults in Vietnam: A systematic review and meta-analysis of prevalence.Medicine · 2026 · Nguyen VK, Duc TQ, Le VA, et al.PMID 42216345DOI 10.1097/MD.0000000000049030
- Probiotics alleviate oral microbiota disruptions induced by Helicobacter pylori eradication with vonoprazan-amoxicillin dual therapy: a randomized double-blind placebo-controlled trial. (An exploratory study).Frontiers in cellular and infection microbiology · 2026 · Wei W, Chen W, Peng R, et al.PMID 42211655DOI 10.3389/fcimb.2026.1740968
- Potassium-competitive acid blockers for Helicobacter pylori eradication in pediatrics: a narrative review of pharmacologic rationale, clinical evidence, and practical considerations.Frontiers in cellular and infection microbiology · 2026 · Gu B, Le J, Cai H, et al.PMID 42211654DOI 10.3389/fcimb.2026.1810850
- New Insights into CRISPR-like Arrays in Helicobacter pylori: An Exploratory Analysis from Genomic Data.Pathogens (Basel, Switzerland) · 2026 · Camacho-Aguilar P, Delgado-Nungaray JA, Reynaga-Delgado E, et al.PMID 42198588DOI 10.3390/pathogens15050461
Clinical trials
The 10 most recently updated of 844 ClinicalTrials.gov registrations naming Helicobacter Pylori as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric CancerRecruiting · Phase 2 · Interventional · 180 enrolled · Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT06510010updated 2026-06-10
- Effect of PPIs on Stool DNA Test for H. PyloriRecruiting · Observational · 25 enrolled · Shanghai Jiao Tong University School of MedicineNCT07516262updated 2026-06-05
- Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter PyloriRecruiting · Interventional · 25 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)NCT06871579updated 2026-06-03
- Vonoprazan High-Dose Dual VS Levofloxacin ConcomitantNot yet recruiting · Phase 4 · Interventional · 150 enrolled · Damascus HospitalNCT07624422updated 2026-06-03
- Biological Optimization Versus Standard Care in Post-POEM Achalasia Patients (BIO-POEM)Active not recruiting · Interventional · 166 enrolled · Asian Institute of Gastroenterology, IndiaNCT07620899updated 2026-06-02
- Changes Associated With H. Pylori and Gastric CarcinogenesisActive not recruiting · Observational · 110 enrolled · Weill Medical College of Cornell UniversityNCT02164409updated 2026-06-01
- The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter PyloriNot yet recruiting · Phase 3 · Interventional · 556 enrolled · Xuanzhu Biopharmaceutical Co., Ltd.NCT07606833updated 2026-05-26
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled TrialCompleted · Interventional · 640 enrolled · Zhongshan Hospital (Xiamen), Fudan UniversityNCT06977841updated 2026-05-19
- Levofloxacin-Based Sequential Therapy Versus Bismuth Quadruple Therapy for Helicobacter Pylori EradicationNot yet recruiting · Interventional · 90 enrolled · University of Health Sciences LahoreNCT07574983updated 2026-05-08
- Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:Recruiting · Phase 1 · Interventional · 54 enrolled · Zagazig UniversityNCT07574879updated 2026-05-08
Frequently asked questions
- What is Helicobacter Pylori used for?
- According to FDA labeling, Helicobacter Pylori carries indications including: HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to H. Pylori infection including upper abdominal pain or discomfort, loss of appetite, belching, nausea, vomiting and fatigue.** **These statements are based upon homeopathic principles.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
Note. Data for
helicobacter-pylori is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.